CN106163537A - 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性 - Google Patents

心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性 Download PDF

Info

Publication number
CN106163537A
CN106163537A CN201480063400.5A CN201480063400A CN106163537A CN 106163537 A CN106163537 A CN 106163537A CN 201480063400 A CN201480063400 A CN 201480063400A CN 106163537 A CN106163537 A CN 106163537A
Authority
CN
China
Prior art keywords
arg
lys
phe
aromatic
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480063400.5A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
亚历山大·V·比尔克
保罗·萨博
布莱恩·尹格·赵
玛格丽塔·任
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN106163537A publication Critical patent/CN106163537A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480063400.5A 2013-09-30 2014-09-29 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性 Pending CN106163537A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884722P 2013-09-30 2013-09-30
US61/884,722 2013-09-30
PCT/US2014/058049 WO2015048647A1 (en) 2013-09-30 2014-09-29 Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Publications (1)

Publication Number Publication Date
CN106163537A true CN106163537A (zh) 2016-11-23

Family

ID=52744565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480063400.5A Pending CN106163537A (zh) 2013-09-30 2014-09-29 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性

Country Status (7)

Country Link
US (1) US20160375088A1 (https=)
EP (1) EP3052115A4 (https=)
JP (2) JP6434523B2 (https=)
CN (1) CN106163537A (https=)
AU (2) AU2014324580B2 (https=)
CA (1) CA2925757A1 (https=)
WO (1) WO2015048647A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
CN114269768A (zh) * 2019-10-16 2022-04-01 纳特恩斯株式会社 用于改善记忆力和预防或改善认知功能障碍的肽及包含该肽的组合物、及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CA3020393A1 (en) * 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1787831A (zh) * 2003-02-04 2006-06-14 科内尔研究基金会 用于防止线粒体通透性改变的方法
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
WO2012174117A2 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307219A4 (en) * 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1787831A (zh) * 2003-02-04 2006-06-14 科内尔研究基金会 用于防止线粒体通透性改变的方法
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
WO2012174117A2 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
CN114269768A (zh) * 2019-10-16 2022-04-01 纳特恩斯株式会社 用于改善记忆力和预防或改善认知功能障碍的肽及包含该肽的组合物、及其制备方法

Also Published As

Publication number Publication date
JP6434523B2 (ja) 2018-12-05
AU2014324580B2 (en) 2020-02-27
AU2020203424A1 (en) 2020-06-11
JP2019052158A (ja) 2019-04-04
JP2016533392A (ja) 2016-10-27
EP3052115A4 (en) 2017-09-27
EP3052115A1 (en) 2016-08-10
AU2014324580A1 (en) 2016-04-21
WO2015048647A1 (en) 2015-04-02
CA2925757A1 (en) 2015-04-02
US20160375088A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
JP6839490B2 (ja) ミトコンドリア疾患の治療のための方法
JP7072692B2 (ja) バース症候群の予防または治療のための方法及び組成物
JP2019069985A (ja) ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2016000750A (ja) 芳香族カチオン性ペプチドおよびその使用
AU2020203424A1 (en) Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
JP2020059720A (ja) 芳香族陽イオン性ペプチドおよびその使用
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
CN107312066A (zh) 芳香族阳离子肽及其用途
JP6480921B2 (ja) コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK40097140A (zh) 治疗线粒体疾病的方法
AU2019392670A1 (en) Methods and compositions for the treatment of Sengers syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161123